ArticleBrain sciences2017
Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols.
Article in Brain sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.European child & adolescent psychiatry · 2024Pooled it
- Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study.Pharmacopsychiatry · 2022Trial
- Tourette syndrome.Nature reviews. Disease primers · 2026Review
- Alternative Treatment of the Resistant-to-Treatment Tourette Syndrome-A Systematic Review.Journal of clinical medicine · 2026Review
- Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.Pharmacopsychiatry · 2024Review
- Therapeutic use of medical Cannabis in neurological diseases: a clinical update.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- The Rush Video-Based Tic Rating Scale-Revised: A Practice-Oriented Revision.Movement disorders clinical practice · 2023Article
- Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study.Behavioural neurology · 2022Article
- Review
- Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray.Tremor and other hyperkinetic movements (New York, N.Y.) · 2021Article
- Association of a Variant ofFrontiers in genetics · 2020Article
- Family-Based Analysis Combined with Case-Controls Study Implicate Roles of PCNT in Tourette Syndrome.Neuropsychiatric disease and treatment · 2020Article
- Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome.Medical cannabis and cannabinoids · 2019Article
- Review
- Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey.Cannabis and cannabinoid research · 2019Article
- Merging the Pathophysiology and Pharmacotherapy of Tics.Tremor and other hyperkinetic movements (New York, N.Y.) · 2018Review
- Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration.International journal of physical medicine & rehabilitation · 2018Article
- Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.Drug, healthcare and patient safety · 2018Review
- Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff/day (= 100 μL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 × 3 puffs/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.